The US Food and Drug Administration (FDA) has approved a clinical study of Pentixapharm’s CXCR4-targeted theranostic programme in haemato-oncology, following a 30-day safety review of two Investigational New Drug (IND) applications.  The two IND submissions support the single PENTHERA Phase I/II protocol, which evaluates the combined use of PentixaFor imaging and [⁹⁰Y]Y-PentixaTher as targeted bone […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!